Inhibitors of glutamate release from breast cancer cells; new targets for cancer-induced bone-pain
暂无分享,去创建一个
Gurmit Singh | Jennifer Fazzari | Hanxin Lin | Cecilia Murphy | Robert Ungard | J. Fazzari | R. Ungard | G. Singh | C. Murphy | Hanxin Lin
[1] J. Waddington,et al. Agonist and antagonist properties of benzazepine and thienopyridine derivatives at the D1 dopamine receptor , 1989, Neuropharmacology.
[2] R. Edwards,et al. Secretion of L‐glutamate from osteoclasts through transcytosis , 2006, The EMBO journal.
[3] H. Lee,et al. Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies , 2011, Clinical Cancer Research.
[4] H. Galbo,et al. Elevated muscle interstitial levels of pain-inducing substances in symptomatic muscles in patients with polymyalgia rheumatica , 2011, PAIN.
[5] A. Dickenson,et al. The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord. , 1997, General pharmacology.
[6] R. Coleman. Skeletal complications of malignancy , 1997, Cancer.
[7] F. Orr,et al. Morphological, histomorphometric, and microstructural alterations in human bone metastasis from breast carcinoma. , 2002, Bone.
[8] S. Carlton. Peripheral excitatory amino acids. , 2001, Current opinion in pharmacology.
[9] N. Bruchovsky,et al. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc− cystine transporter: a new action for an old drug , 2001, Leukemia.
[10] T. Skerry. The role of glutamate in the regulation of bone mass and architecture. , 2008, Journal of musculoskeletal & neuronal interactions.
[11] P. Kuchel,et al. Glutamine and α‐ketoglutarate as glutamate sources for glutathione synthesis in human erythrocytes , 2011, The FEBS journal.
[12] J. Kebabian,et al. Multiple receptors for dopamine , 1979, Nature.
[13] S. Willard,et al. Glutamate Signaling in Benign and Malignant Disorders: Current Status, Future Perspectives, and Therapeutic Implications , 2013, International journal of biological sciences.
[14] C. Speyer,et al. Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer , 2012, Breast Cancer Research and Treatment.
[15] P. Mantyh,et al. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons , 2000, Neuroscience.
[16] Bonnie F. Sloane,et al. Metabotropic Glutamate Receptor-1 Contributes to Progression in Triple Negative Breast Cancer , 2014, PloS one.
[17] E. Seidlitz,et al. Inhibition of breast cancer-cell glutamate release with sulfasalazine limits cancer-induced bone pain , 2014, PAIN®.
[18] M. Salter,et al. Glutamate receptor phosphorylation and trafficking in pain plasticity in spinal cord dorsal horn , 2010, The European journal of neuroscience.
[19] Xuechu Zhen,et al. D1 dopamine receptor agonists mediate activation of p38 mitogen-activated protein kinase and c-Jun amino-terminal kinase by a protein kinase A-dependent mechanism in SK-N-MC human neuroblastoma cells. , 1998, Molecular pharmacology.
[20] P. S. Sillevis Smitt,et al. A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: a critical appraisal. , 2009, European journal of cancer.
[21] S. Mercadante. Malignant bone pain: pathophysiology and treatment , 1996, Pain.
[22] I. Núñez de Castro,et al. Nitrogen movement between host and tumor in mice inoculated with Ehrlich ascitic tumor cells. , 1984, Cancer research.
[23] T. Ishii,et al. A novel function of glutamine in cell culture: Utilization of glutamine for the uptake of cystine in human fibroblasts , 1988, Journal of cellular physiology.
[24] Jin Namkoong,et al. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. , 2007, Cancer research.
[25] L. Arendt-Nielsen,et al. Effects of subcutaneous administration of glutamate on pain, sensitization and vasomotor responses in healthy men and women , 2006, Pain.
[26] Ying Huang,et al. Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. , 2006, Cancer letters.
[27] Ralph J Deberardinis,et al. Brick by brick: metabolism and tumor cell growth. , 2008, Current opinion in genetics & development.
[28] I. Eyüpoglu,et al. xCT modulation in gliomas: relevance to energy metabolism and tumor microenvironment normalization. , 2010, Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft.
[29] N. Kirma,et al. Vanilloids induce oral cancer apoptosis independent of TRPV1. , 2014, Oral oncology.
[30] H. Sontheimer,et al. Glioma cells release excitotoxic concentrations of glutamate. , 1999, Cancer research.
[31] D. Johnson,et al. The growth inhibitory properties of a dopamine agonist (SKF 38393) on MCF-7 cells. , 1995, Anti-cancer drugs.
[32] T. Jessell,et al. Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation. , 1989, Science.
[33] Gurmit Singh,et al. Cancer cell lines release glutamate into the extracellular environment , 2009, Clinical & Experimental Metastasis.
[34] Toshiyuki Sato,et al. Bromocriptine, an ergot alkaloid, inhibits excitatory amino acid release mediated by glutamate transporter reversal. , 2010, European journal of pharmacology.
[35] Harald Sontheimer,et al. Glutamate Release by Primary Brain Tumors Induces Epileptic Activity , 2011, Nature Medicine.
[36] W. Souba,et al. Determinants of glutamine dependence and utilization by normal and tumor‐derived breast cell lines , 1998, Journal of cellular physiology.
[37] K. Westlund,et al. Excitatory amino acid profiles of synovial fluid from patients with arthritis. , 2000, The Journal of rheumatology.
[38] E. Seidlitz,et al. Extracellular glutamate alters mature osteoclast and osteoblast functions. , 2010, Canadian journal of physiology and pharmacology.
[39] E. White,et al. Metabotropic Glutamate Receptor 1 (Grm1) Is An Oncogene In Epithelial Cells , 2012, Oncogene.
[40] B. Aggarwal,et al. Capsazepine, a TRPV1 antagonist, sensitizes colorectal cancer cells to apoptosis by TRAIL through ROS-JNK-CHOP-mediated upregulation of death receptors. , 2012, Free radical biology & medicine.
[41] K. Brakspear,et al. Glutamate signaling in bone , 2012, Front. Endocrin..
[42] T. Ishii,et al. Cloning and Expression of a Plasma Membrane Cystine/Glutamate Exchange Transporter Composed of Two Distinct Proteins* , 1999, The Journal of Biological Chemistry.
[43] Takahiro Takano,et al. Glutamate release promotes growth of malignant gliomas , 2001, Nature Medicine.
[44] M. Fallon,et al. Translational medicine: cancer pain mechanisms and management. , 2008, British journal of anaesthesia.
[45] J. Matés,et al. Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. , 2013, Current molecular medicine.
[46] A. Buckley,et al. Sulfasalazine‐induced cystine starvation: Potential use for prostate cancer therapy , 2007, The Prostate.
[47] H. Sontheimer,et al. Inhibition of Cystine Uptake Disrupts the Growth of Primary Brain Tumors , 2005, The Journal of Neuroscience.
[48] L. Kühn,et al. Glycoprotein-associated amino acid exchangers: broadening the range of transport specificity , 2000, Pflügers Archiv.
[49] P. Mantyh,et al. Bone cancer pain , 2010, Annals of the New York Academy of Sciences.
[50] K. Westlund,et al. Amino acid release into the knee joint: key role in nociception and inflammation , 2000, Pain.
[51] S. Grillner,et al. Excitatory amino acids and synaptic transmission: the evidence for a physiological function. , 1990, Trends in pharmacological sciences.
[52] S. Bannai,et al. Transport interaction of L-cystine and L-glutamate in human diploid fibroblasts in culture. , 1980, The Journal of biological chemistry.
[53] J. Gray,et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. , 2013, Cancer cell.
[54] U. R. Chowdhury,et al. Dopamine Increases the Efficacy of Anticancer Drugs in Breast and Colon Cancer Preclinical Models , 2008, Clinical Cancer Research.
[55] H P Rang,et al. Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin , 1992, British journal of pharmacology.
[56] M. Brann,et al. Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[57] K. Omote,et al. Formalin-induced release of excitatory amino acids in the skin of the rat hindpaw , 1998, Brain Research.
[58] E. Hinoi,et al. Possible involvement of glutamatergic signaling machineries in pathophysiology of rheumatoid arthritis. , 2011, Journal of pharmacological sciences.
[59] S. Bannai. Exchange of cystine and glutamate across plasma membrane of human fibroblasts. , 1986, The Journal of biological chemistry.
[60] Gurmit Singh,et al. Cancer cells release glutamate via the cystine/glutamate antiporter. , 2010, Biochemical and biophysical research communications.
[61] R. Deberardinis,et al. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis , 2007, Proceedings of the National Academy of Sciences.
[62] S. Mercadante,et al. Predictive factors in advanced cancer pain treated only by analgesics , 1992, Pain.